ValuEngine cut shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report released on Thursday morning, ValuEngine reports.

Other equities research analysts also recently issued reports about the company. Maxim Group set a $32.00 target price on Omeros and gave the company a buy rating in a report on Friday, August 9th. Zacks Investment Research downgraded Omeros from a buy rating to a hold rating in a report on Wednesday, October 30th. HC Wainwright reiterated a buy rating and set a $35.00 target price on shares of Omeros in a report on Tuesday, November 5th. Wedbush reiterated a hold rating and set a $18.00 target price on shares of Omeros in a report on Monday, October 28th. Finally, Needham & Company LLC reiterated a hold rating on shares of Omeros in a report on Wednesday, November 13th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $25.60.

Shares of Omeros stock traded up $0.09 during trading hours on Thursday, reaching $13.29. The stock had a trading volume of 409,000 shares, compared to its average volume of 494,192. The firm has a 50 day simple moving average of $15.17 and a two-hundred day simple moving average of $16.82. The firm has a market capitalization of $687.02 million, a price-to-earnings ratio of -5.99 and a beta of 2.78. Omeros has a 1 year low of $10.30 and a 1 year high of $20.92.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08. The firm had revenue of $29.86 million during the quarter, compared to analysts’ expectations of $27.19 million. The business’s revenue for the quarter was up 547.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.81) earnings per share. On average, equities analysts predict that Omeros will post -1.2 earnings per share for the current fiscal year.

In related news, Director Thomas J. Cable sold 5,000 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $15.12, for a total transaction of $75,600.00. Following the sale, the director now directly owns 35,067 shares in the company, valued at approximately $530,213.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 12.80% of the company’s stock.

Several large investors have recently made changes to their positions in OMER. Cetera Advisors LLC purchased a new stake in Omeros during the 3rd quarter worth approximately $180,000. Bourgeon Capital Management LLC purchased a new stake in Omeros during the 3rd quarter worth approximately $41,000. SG Americas Securities LLC increased its holdings in Omeros by 61.0% during the 3rd quarter. SG Americas Securities LLC now owns 130,823 shares of the biopharmaceutical company’s stock worth $2,136,000 after purchasing an additional 49,548 shares during the last quarter. California Public Employees Retirement System increased its holdings in Omeros by 62.0% during the 3rd quarter. California Public Employees Retirement System now owns 112,013 shares of the biopharmaceutical company’s stock worth $1,829,000 after purchasing an additional 42,874 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC increased its holdings in Omeros by 7.0% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 25,680 shares of the biopharmaceutical company’s stock worth $419,000 after purchasing an additional 1,680 shares during the last quarter. Institutional investors and hedge funds own 53.87% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Stock Symbol

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.